These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 28603071)

  • 101. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
    Antlanger M; Dust T; Reiter T; Böhm A; Lamm WW; Gornicec M; Willenbacher E; Nachbaur D; Weger R; Rabitsch W; Rasoul-Rockenschaub S; Worel N; Lechner D; Greinix H; Keil F; Gisslinger H; Agis H; Krauth MT
    BMC Cancer; 2018 Oct; 18(1):1008. PubMed ID: 30342509
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
    Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
    [TBL] [Abstract][Full Text] [Related]  

  • 104. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
    Hong S; Rybicki L; Abounader D; Bolwell BJ; Dean R; Gerds AT; Hamilton BK; Hill BT; Jagadeesh D; Kalaycio M; Liu HD; Pohlman B; Sobecks R; Majhail NS
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1141-1144. PubMed ID: 26995694
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
    Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
    J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma.
    Khouri J; Majhail NS
    Curr Opin Support Palliat Care; 2017 Dec; 11(4):361-365. PubMed ID: 28922292
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis.
    Wudhikarn K; Johnson BM; Inwards DJ; Porrata LF; Micallef IN; Ansell SM; Hogan WJ; Paludo J; Villasboas JC; Johnston PB
    Transplant Cell Ther; 2023 Mar; 29(3):176.e1-176.e8. PubMed ID: 36563788
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation.
    Salit RB; Oliver DC; Delaney C; Sorror ML; Milano F
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):654-658. PubMed ID: 28189904
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.
    Paul TM; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Nasta SD; Loren A; Frey N; Perl A; Cohen AD; Weiss BM; Stadtmauer EA; Vogl DT
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):536-40. PubMed ID: 26141214
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.
    Rosko AE; Huang Y; Benson DM; Efebera YA; Hofmeister C; Jaglowski S; Devine S; Bhatt G; Wildes TM; Dyko A; Jones D; Naughton MJ; Byrd JC; Burd CE
    J Geriatr Oncol; 2019 May; 10(3):479-485. PubMed ID: 29983352
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.
    Dhakal B; Giri S; Levin A; Rein L; Fenske TS; Chhabra S; Shah NN; Szabo A; D'Souza A; Pasquini M; Hari P; Hamadani M
    JAMA Netw Open; 2019 Jul; 2(7):e196476. PubMed ID: 31276175
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.
    Nawas MT; Andreadis C; Martin TG; Wolf JL; Ai WZ; Kaplan LD; Mannis GN; Logan AC; Damon LE; Huang CY; Olin RL
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1218-1224. PubMed ID: 30708189
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients.
    Jandial A; Lad D; Jain A; Khadwal A; Singh C; Prakash G; Suri V; Sreedharanunni S; Sachdeva MUS; Ray P; Varma N; Varma S; Malhotra P
    Transpl Infect Dis; 2023 Oct; 25(5):e14123. PubMed ID: 37573150
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Hospital Associated Disability among Older Adults with Plasma Cell Disorders Receiving Autologous Stem Cell Transplant.
    Kidwell K; Bal S; Godby K; Ravi G; Costa LJ; Shrestha S; Salzman D; Hayes T; Williams GR; Bhatia S; Giri S
    Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38876427
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes.
    DeFilipp Z; Troschel FM; Qualls DA; Li S; Kuklinski MW; Kempner ME; Hochberg E; Chen YB; El-Jawahri A; Fintelmann FJ
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1741-1747. PubMed ID: 29496561
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.
    Khera N; Storer B; Flowers ME; Carpenter PA; Inamoto Y; Sandmaier BM; Martin PJ; Lee SJ
    J Clin Oncol; 2012 Jan; 30(1):71-7. PubMed ID: 22147737
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma.
    Paquin A; Visram A; Kumar SK; Gertz MA; Cantwell H; Buadi FK; Lacy MQ; Dispenzieri A; Dingli D; Hwa L; Fonder A; Hobbs M; Hayman SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Rajkumar SV
    Blood Cancer J; 2020 Aug; 10(8):87. PubMed ID: 32859899
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort.
    Saeed H; Yalamanchi S; Liu M; Van Meter E; Gul Z; Monohan G; Howard D; Hildebrandt GC; Herzig R
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):90-95. PubMed ID: 29398592
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population.
    Barth D; Singleton M; Monohan G; McClune B; Adams V
    Cell Transplant; 2022; 31():9636897221080385. PubMed ID: 35225031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.